Outlook on the Worldwide Anti-tuberculosis Therapeutics Market to 2024 – Driven by the Rising Incidence of MDR & XDR Cases in Developing Countries

Ads

You May Also Like

Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

- TransCon CNP preliminary phase 1 data support target product profile and further validates ...

Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) ...

Five Prime Therapeutics to Present at the Barclays Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...